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S87.e2 Geller et alIncidence and mortality rates of melanoma throughout most of the developed world have increased in the
past 25 years. We propose that reduction of deaths from melanoma can be best enhanced by strong
collaborations between experts in dermatology, primary care, oncology, cancer education and health
systems research, epidemiologists, and behavioral scientists, among others. Public and professional
educational campaigns should be guided by an understanding of 3 underlying but overlapping roots:
epidemiology and preventable mortality (an understanding of who is most likely to be given the diagnosis
of thick or late-stage melanoma), biology (an investigation of tumor types that are relatively common but
potentially most lethal), and sociology (an analysis of the changes needed in social structures to improve
access to those most in need of early detection programs). We review these major concepts, concentrating
on the key risk factors for advanced melanoma. ( J Am Acad Dermatol 2011;65:S87.e1-9.)
Key words: early detection; education; melanoma; physician; screening; skin cancer.CAPSULE SUMMARY
d Middle-aged and older men and persons
of low socioeconomic status have
disproportionately high rates of
advanced melanoma.
d Education and screening need to be
focused and targeted to groups at most
risk.
d Public health campaigns to reduce
deaths from melanoma must be
collaborative across multiple disciplines.Melanoma incidence and
mortality rates throughout
most of the developed world
have increased sharply in the
past 3 decades,1-4 whereas
education and screening
continue to be underused.5
We highlight emerging in-
cidence and mortality trends,
provide data supportive of
public health interventions
to reduce melanoma mortal-
ity, and explore options for
reducing mortality including
screening trials and public and professional educa-
tion to promote early detection of disease.
We propose that reducing melanoma mortality
will best be accomplished through early identifica-
tion, education, research, and advocacy. There also
needs to be a focus on the emerging disproportion-
ate burden of melanoma mortality and late-stage
disease among white men ages 50 years and older
and those persons of lower socioeconomic status
(SES) and a practical understanding of physician
practice patterns; multiple studies uniformly agree
that physicians find thinner melanoma than the
patient or their partners.6 Such evidence points to
the need for a strategy that improves the percentage
of primary care physicians who are skilled and
devote themselves to routine examination of the
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ADVANCED
MELANOMA
In contrast to other pre-
ventable cancers for which
mortality has markedly de-
creased since 1975, mela-
noma mortality has only
recently stabilized,1,4 likely
because fewer than a quarter
of Americans report receipt
of a skin examination.5
Middle-aged and older
men, persons of lower SES,and individuals given the diagnosis of the nodular
melanoma (NM) subtype are at greatest risk of
advanced disease.
Middle-aged and older men
As described by Jemal et al4 and Watson et al7 in
this supplement, disproportionate mortality is driven
by unabated increases in the incidence rate for
middle-aged and older men. For example, since
1975, incidence rates have more than doubled for
men ages 50 to 59 years, quadrupled for men ages 60
to 69 years, and multiplied 7-fold for the oldest men,
ages 80 years and older.4
Hispanics
Although melanoma diagnoses are rare in persons
of color,8,9 reports presented in this supplement findssed in this supplement are those of
ecessarily reflect the opinions,
cial position of the journal editors or
ontrol and Prevention.
23, 2011.
ler, MPH, RN, Department of Society,
d Health, Harvard School of Public
677 Huntington Avenue, Room 718,
: ageller@hsph.harvard.edu.
Abbreviations used:
AAD: American Academy of Dermatology
CI: confidence interval
NM: nodular melanoma
OR: odds ratio
QALY: quality-adjusted life year
SES: socioeconomic status
SSE: skin self-examination
SSM: superficial spreading melanoma
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thick lesions amongHispanics.10 Furthermore, a recent
analysis of melanoma incidence among those who
self-identified as Hispanic and non-Hispanic white
patients in California has demonstrated that lower SES
is more strongly associated with thicker tumors
([2 mm) in Hispanics compared with whites (relative
risk 2.18, 95%confidence interval [CI] 1.73-2.74 vs 1.48,
95% CI 1.37-1.61, respectively).11 Compared with
higher SES patients, lower SES male Hispanic patients
had fewer superficial spreading melanomas (SSM),
more nodular and acral lentiginous melanomas, and
more frequent leg and hip melanomas.11
Social class and melanoma
The data presented by Singh et al12 in this sup-
plement describe the association between the SES
of a given area and melanoma incidence. Earlier,
Reyes-Ortiz et al13 summarized the studies related to the
effect of SES on melanoma stage at diagnosis rather
than incidence alone. Of the 12 studies analyzed
(8 population-based), all found increased rates of
advanced-stage melanoma or decreased survival in
lower SES individuals. Various indices of social class
were used including occupation, education, physician
supply, and poverty rates.13 Using Surveillance,
Epidemiology, and End Results and California
Cancer Registry data (1988-2004), Linos et al14 found
an increasingly higher rate of thicker, poor-
prognosis melanomas for persons of lower SES.
Pollitt et al15 linked California Cancer Registry rec-
ords with Medicaid enrollment status and found that
late-stage disease was diagnosed in 27% of Medicaid
enrollees compared with only 9% of non-Medicaid
enrollees statewide.15
Individuals given the diagnosis of NM
Worldwide, the NM subtype accounts for a dispro-
portionate number of newly diagnosed thick mela-
noma ($ 2 mm). In an analysis of more than 35,000
invasivemelanomas from theNational Cancer Institute
Surveillance, Epidemiology, and End Results data
(1988-1999), NM comprised only 9% of all lesions but
accounted for nearly 50% of melanomas 2 mm or
deeperwhenmelanomasnototherwise specifiedwereexcluded. Median thickness of NM changed little from
1988 to 1991 (2.14 mm) through 1995 to 1999 (2.16
mm) andNMwere nearly 4-fold thicker than SSM (0.54
mm, median thickness).16
To assess differences between Queensland,
Australia patients with thin (# 2.00 mm) and thick
($ 2.01mm)NM,Geller et al17 evaluated factors such
as demographics, melanoma detection patterns, tu-
mor visibility, and physician screening for NM alone
and compared clinical presentation and anatomic
location of NM with SSM. During this 4-year period,
369patientswithNMwere interviewed, ofwhom57%
were given a diagnosis of melanoma less than or
equal to 2.00 mm. Men, older individuals, and those
who had not been screened by a physician in the past
3 years were more likely to have nodular tumors of
greater thickness. The thickest NMs ($ 4 mm) were
also most common in individuals who had not been
screened by a physician within the past 3 years
(odds ratio [OR] 3.75; 95% CI 1.47-9.59). Of patients,
46% with thin NM (# 2.00 mm) reported a change in
color, midway between patients with thin SSM (64%)
and patients with thickNM ([2.00mm) (26%).17Most
recent dermatoscopic analyses of thinNM found them
to have characteristics such as a blue-white veil,
structureless areas, and atypical vascular structures.18
REDUCING MORTALITY VIA EARLY
IDENTIFICATION AND EDUCATION
Four complementary strategies for the reduction
of melanoma deaths are reviewed: (1) conduct of
early detection trials, (2) clinician education, (3) NM
research, and (4) targeted education for reaching
population subgroups at greatest risk of advanced-
stage disease.
Conduct of early detection trials
Organized efforts to detect melanoma early are
ongoing and can be enhanced in multiple venues,
such as community-wide screenings, dermatology-
led mass screenings, nondermatologist physician or
health care professional surveillance, skin self-
examination (SSE), specialized pigmented lesion
clinics, and via public education targeted to individ-
uals at greatest risk for this disease.
Most recently, the US Preventive Services Task
Force concluded that evidence is lacking that
routine skin examination of the adult general
population by primary care clinicians is effective
in reducing mortality or morbidity from skin
cancer in the general population.19 English-
language studies were selected by the Task Force
to answer the following key question: Does
screening in asymptomatic persons with whole-
body examination by a primary care clinician or by
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from skin cancer?19
In consideration of a randomized trial in the
United States, estimated costs and numbers needed
to screen were recently projected.20 Based on
current melanoma incidence and mortality, a ran-
domized trial of melanoma screening with a 20%
impact on mortality would require a screened study
population of 350,000 Americans (and 700,000 con-
trol subjects) ages 45 years and older with a 4-year
intervention period and 8 years passive follow-up at
an estimated cost of $30million to $40 million. Large-
scale trials have used mortality as proper end points.
However, with compelling data confirming the use-
fulness of tumor thickness and stage of disease as a
proxy for mortality, melanoma severity (with tumor
thickness and/or sentinel lymph node positivity as
key components) should be addressed as part of any
cost projections.20
Numerous attempts have been made to collect
evidence demonstrating the effectiveness of mela-
noma screening. These include in chronologic order:
screening of self-selected individuals in the
American Academy of Dermatology (AAD) pro-
grams in the United States,21,22 the Lawrence
Livermore National Laboratory Study,23 a community
randomized trial in Australia,24-26 and national
screening in Germany.27 Major studies have also
included a recent case-control study in Australia and
cost-effectiveness modeling.28,29 These are briefly
reviewed.
The AAD free skin cancer screening programs
have reached more than 1.5 million Americans. Of
screenees, 65% had at least one risk factor for
melanoma and 33% reported a changing mole.
Among all screenees, nearly 80% did not have a
regular dermatologist, 78% reported no prior AAD
skin cancer screening, 60% had never had their skin
checked by any doctor, and 51% reported that they
would not have seen a doctor for skin cancer without
the free screening. Among nearly 250,000 screenees,
363melanomaswere diagnosede98% of which were
stage I melanomas.21,22 In other settings, workplace
screening at the Lawrence Livermore National
Laboratory yielded a progressive decreasing inci-
dence of thicker melanoma and subsequently no
melanoma deaths during the intensive screening
program.23
The higher rates of melanoma in Australia allowed
researchers to plan and implement a randomized
trial of population screening.24-26 Although the plan
called for randomizing a total of 44 Queensland,
Australia, communities, only 18 were initially ran-
domized to intervention (n = 9) and control (n = 9)
towns before the study funding was withdrawn. Thetrial’s 3 components included: (1) a community
education component, which aimed to provide ac-
curate information about melanoma and screening
to residents; (2) an education and support compo-
nent for medical practitioners, which aimed to
increase awareness of the program and to improve
doctors’ skills in screening for and diagnosing mel-
anoma; and (3) the provision of free skin screening
services.24-26 Uptake of the whole-body skin cancer
examinationwasmeasured by surveys of residents in
intervention and control towns. Baseline rates were
similar in intervention and control towns (11.2% and
11.3%); however, rates jumped 2 years later to 34.8%
in intervention towns while remaining constant
(13.9%) in control communities.26 In general, screen-
ings were performed by general practitioners. Tumor
thickness is unknown. Community-based or clinic-
based randomized studies with tumor thickness or
mortality end points are needed.
In Germany, a major skin cancer screening pro-
gram is underway. The goal is to screen every citizen
ages 35 years and older (45 million individuals) and
to date, more than 10 million examinations have
taken place; the major outcome will be reduction in
mortality in the period before and upon completion
of the screening program. The goal of training the
nation’s 45,000 physicians with an 8-hour training
program has been nearly reached.27
Aitken et al28 reported results from a population-
based case-control, telephone-based study of all
Queensland, Australia, residents aged 20 to 75 years
with a histologically confirmed first primary invasive
cutaneous melanoma diagnosed between January
2000 and December 2003. Whole-body clinical skin
examination in the 3 years before diagnosis was
associated with a 14% lower risk of being given a
diagnosis of a thick melanoma ([0.75mm) (OR 0.86;
95% CI 0.75-0.98). Screening was associated with a
38% higher risk of being given a diagnosis of a thin
invasive melanoma (# 0.75 mm) (OR 1.38; 95% CI
1.22-1.56). This is the strongest evidence to date that
whole-body clinical skin examination reduces the
incidence of thick melanoma and these results
suggest that screening would reduce melanoma
mortality.28
In a cost-effectiveness model, Losina et al29 found
that one-time melanoma screening of the general
population was cost-effective compared with other
cancer screening programs in the United States. In the
general population, one-time, every 2-year, and an-
nual screening saved2.5, 8.8, and10.2quality-adjusted
life years (QALY) per 1000 people screened, with
incremental cost-effectiveness ratios of $7300/QALY,
$58,000/QALY, and $450,500/QALY for one-time,
every 2-year, and annual screening, respectively.29
Table I. Professional education: Rationale for
primary care provider’s role in early detection
d Most Americans do not have a dermatologist
d Only 25% of white Americans have been screened
d Middle-aged and older men make at least 3-4 visits per
year to a physician or medical care facility
d Nearly 2/3 of cases report seeing physician in year
before diagnosis
d Many lesions are not easily visible to patient
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associated with SSE. Berwick et al30 conducted a
case-control study and found that SSE could poten-
tially reduce mortality as a result of melanoma by
63%. Two other observational studies have been
conducted. More recently, SSE was found to be a key
predictor for melanoma less than 1 mm in thick-
ness.31 In a study of 321 dermatology clinic patients,
Pollitt et al32 found that using a melanoma picture as
a SSE aidwas strongly associatedwith reduced tumor
thickness (adjusted ratio 0.75; 95% CI 0.66-0.85).
Whether patients can consistently find early mela-
noma, particularly on hard-to-see sites, is question-
able and deserves further scrutiny.
Janda et al33 recently reported on the successful
recruitment of men aged 50 years or older to a
randomized trial using a 12-minute intervention
video toward men 50 years or older. Of more than
900 men recruited for the study, 13% reported
conducting a whole-body SSE and 39% reported
receiving a full-body clinical skin examination by a
doctor within the past 12 months, with confidence in
finding time for SSE and receiving physician instruc-
tion for SSE related to thorough SSE at baseline.Clinician education
Full-body examinations by either dermatologists
or nondermatologist physicians have both shown
the potential to save lives otherwise lost to mela-
noma. Of the 5 major early detectable cancers
(melanoma, breast, colorectal, prostate, and cervical
cancer), only skin cancer requires an initial visual,
noninvasive examination.
The rationale is strong for an educational outreach
campaign to primary care providers (Table I). Most
Americans do not have a dermatologist and only 25%
of Americans report ever being screened for mela-
noma.6 Middle-aged and older menmake at least 3 to
4 visits to a physician annually and nearly two thirds
of cases report seeing a physician in the year before
diagnosis.34,35 Moreover, many lesions are on hard-
to-see sites and this finding provides some insightinto why melanoma is discovered earlier by physi-
cians compared with the patient or their partner.
Many recent studies have analyzed tumor thick-
ness by melanoma detector, such as the patient, their
partner, or the physician (dermatologist or non-
dermatologist physician). Nearly all of the studies
have found a favorable tumor thickness for mela-
noma diagnosed by primary care providers at least
0.5 to 1.00 mm thinner.36,37 In a study of cases
diagnosed in Michigan and California, 69% of
physician-diagnosed melanomas were less than
1 mm compared with 33% of self-detected melano-
mas.36 However, less than half of US physicians
routinely examine the skin for cancer, and neither
medical students nor primary care residents are
adequately trained in skin cancer examination.38-41
Much remains unknown about melanoma discov-
ery patterns and differences between dermatologist
and primary care provider biopsy and referral prac-
tices. Chen et al42 performed a systematic review of
32 studies of melanoma discovery patterns con-
ducted before 2001 and found numerous informa-
tion gaps, including lack of consistent sensitivity and
specificity data, inadequate sample sizes, and data
derived primarily from residents rather than attend-
ing physicians.
Although there are a number of factors promoting
physician-led screening, many barriers persist. In a
regression analysis of factors influencing physician
examination of patients at high risk, lack of time was
the strongest barrier (OR 0.3; 95% CI 0.2-0.6).
Physicians using the most information sources,
such as brochures (OR 2.5; 95% CI 1.3-4.8) were
the most inclined to examine their patients at high
risk (risk factors included: fair skin, many moles, a
few atypical moles, family and/or personal history of
skin cancer, and excessive sun exposure). Physicians
whose patients requested a skin examination were
more likely to examine their patients compared with
physicians whose patients did not request such an
examination (P\ .01).39 Therefore, an educational
campaign that encourages Americans at high risk to
request a thorough screen by their primary care
provider during the routine medical examination
may be warranted.
A number of new World Wide Web sites are
dedicated toward improving the recognition and
triaging of skin lesions by primary care physi-
cians.43,44 Curricula innovators are trying to establish
educational programs tailored to physicians to en-
courage them to integrate a thorough examination as
part of the routine medical visit. For example, at least
30% of all lesions in men are on the back and an
estimated 20% of all melanomas in women are on the
back of the legs.45 Examining lesions on the back
Fig 1. Campaign to improve recognition of back melanoma. Printed with permission.
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cardiac examination should be mainstays of a new
educational curriculum. Ancillary personnel such as
hairdressers and masseuses can be trained to survey
the scalp and back for suspicious lesions.
Nodular melanoma
With the NM subtype comprising a disproportion-
ate share of thick melanoma histology, more re-
search is needed to distinguish tumor and other
factors related to thin versus thick NM at presenta-
tion. The fact that nearly 50% of all NM are diagnosed
at less than 2 mm and that they possess clinical signs
akin to SSM provides reason to believe that there is a
detectable preclinical phase for earlier detection.16
Multifactorial studies should examine differences atthe molecular, epidemiologic, and behavioral levels
for this rapidly growing subtype.
Focused advocacy
Understanding the role that gender and social
class play in melanoma knowledge, attitudes, access
to an initial screening examination, discovery, and
diagnosis is central to narrowing the striking eco-
nomic and gender divide. Middle-aged and older
men, persons of lower SES, and individuals with lack
of access to skilled personalized care are all at greater
risk of advanced-stage disease. Although there are
more than 50 melanoma foundations in the United
States, few focus exclusively on early detection. With
recent analyses finding increasing rates of melanoma
among young women,46 they too should be
Table II. Proportion of melanoma classified by
tumor thicknesseUnited States 1988 to 200656
Tumor thickness,
mm
No. of
cases
No. of
deaths
Cases/
death
Percent of
deaths
\1 91,174 2472 37 27
1.01-2 20,424 2142 9.5 23
2.01-4 11,702 2474 4.7 27
[4 6894 2041 3.7 22
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ing the dangers of tanning.
For the high-risk demographic of older men, the
2000 Institute of Medicine report noted that evidence
does support the benefits of early melanoma detec-
tion and treatment as part of usual medical care but
noted that ‘‘clinicians and patients should continue
to be alert to the common signs of skin cancer.’’47
Special efforts to reachmen ages 50 years or older led
to increased screening as part of the Queensland,
Australia, community-based trial. Men ages 50 years
or older comprised 21% of all participants but
accounted for 49% of all melanoma diagnoses.48 A
famous Australian cricket player’s letter as part of an
overall promotion packet was instrumental in boost-
ing screening rates.
Multiple factors are key to achieving access to
high-quality examinations for at-risk patients. Access
to a consistent primary carepractice is essential for the
detection of early melanoma. Researchers in Nova
Scotia used a billing system to examine access and
continuitywith family practitioners and its association
with melanoma thickness. Patients with multiple
visits to the same physician (rather than to many
different providers) had a lower risk for having a
thicker than 0.75 mm melanoma at time of diagno-
sis.49 Access to care is also illustrated by recent studies
using Medicare data showing that diagnosis by a
dermatologist (as opposed to nondermatologist phy-
sicians) more favorably correlates with melanoma
survival at 2 years.50 In a study of 42 counties in North
Carolina, which included many rural counties,
Stitzenberg et al51 found that greater distance from
an individual’s home to a dermatologist was associ-
atedwith advanced tumor thickness. They speculated
that proximity to dermatologic care was an indicator
of local health resources and noted that patients who
lived in counties with at least one dermatologist
traveled less for care than did patients in communities
with fewer dermatologists. In the United States, mor-
tality of melanoma appears to be higher in states with
fewer dermatologists and in more rural areas.52
Combining Florida state tumor registry data with
state physician data found that each additional der-
matologist per 10,000 residents was associated with a39% increased likelihood of earlier diagnosis.
Roetzheim et al53 suggested that AAD screenings
branch out to areas with the shortest supply of
dermatologists. In a study using US National Health
Interview Survey data, having health insurance and a
usual source of health care were important predic-
tors for skin cancer screening with few differences
between men and women.54 A United Kingdom
study found reluctance to seek advice for a suspect
lesion was most pronounced among persons from
socially deprived districts, suggesting that there
could be significant attitudinal barriers to screening
among certain groups.55
CONCLUSIONS
Lessening the burden of melanoma mortality
requires a better understanding of the factors that
lead to potentially avoidable mortality as a result of
melanoma. Using a match between tumor thickness
(the most well-established prognostic measure for
melanomamortality) and fatal melanomas, Criscione
and Weinstock56 examined the proportion of US
melanoma deaths classified by tumor thickness and
found that 50% of all melanoma deaths occur in
persons with melanoma diagnosed at 2 mm or less.
The case fatality rate changes markedly for melano-
mas diagnosed at less than 1 mm (1 death/37 cases)
compared with 1 death per 10 cases for melanomas
diagnosed between 1.01 and 2.00 mm. The extent to
which modifiable and behavioral factors play a role
in delayed diagnosis, late treatment, or late discovery
of lesions merits further study and holds an impor-
tant key to reducing unnecessary deaths from
melanoma (Table II).55 Most importantly, strong
differences in case fatality between lesions less
than 1 mm versus those between 1 and 2 mm
requires a full-scale campaign (using tools such as
dermatoscopy) to detect most curable melanomas.
Currently, tumor thickness is collected in some but
not all cancer registries, and data are not reported
nationally. Comprehensive collection and reporting
of this variable would enable improved surveillance
of melanoma detection, especially in states with few
dermatologists and in more rural areas.
Low screening rates in the presence of persistently
increasing but avoidable mortality prompt a call for
broad-scale and innovative approaches, including
ways to make screening more available to under-
served individuals, targeted education to the high-
risk public, and early professional education to
health professional students in all disciplines.
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